The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept: Commentary

Tom Huizinga*, Peter Nigrovic, Eric Ruderman, Hendrik Schulze-Koops

*Corresponding author for this work

Research output: Contribution to journal › Comment/debate › peer-review

1 Scopus citations

Fingerprint

Dive into the research topics of 'The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept: Commentary'. Together they form a unique fingerprint.